Contraception for women with health problems.
Investigational data collected during FDA-monitored clinical trial stem from populations that are sharply defined so as to exclude commonly encountered clinical pathology. This is certainly the case with testing of new contraceptive agents in which patients with obesity, hypertension, altered glucose metabolism, and various endocrine disorders are screened out. What happens in the real world of clinical practice when these patients seek contraceptive counseling? This article examines some of these everyday occurrences.
Corson
S L
SL
Department of Obstetrics and Gynecology, Thomas Jefferson University School of Medicine, Philadelphia, USA.
D001778:Blood Coagulation Disorders; D002318:Cardiovascular Diseases; D002986:Clinical Trials as Topic; D003267:Contraception / Q000379:methods; D003271:Contraceptive Agents, Female / Q000009:adverse effects; D000075202:Contraindications; D003920:Diabetes Mellitus; D004700:Endocrine System Diseases; D005260:Female; D006801:Humans; D006949:Hyperlipidemias; D009422:Nervous System Diseases; D012307:Risk Factors; D016387:Women's Health
D003271:Contraceptive Agents, Female